AU2001249380A1 - Compositions and methods for generating an immune response utilizing alphavirus-based vector systems - Google Patents

Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Info

Publication number
AU2001249380A1
AU2001249380A1 AU2001249380A AU4938001A AU2001249380A1 AU 2001249380 A1 AU2001249380 A1 AU 2001249380A1 AU 2001249380 A AU2001249380 A AU 2001249380A AU 4938001 A AU4938001 A AU 4938001A AU 2001249380 A1 AU2001249380 A1 AU 2001249380A1
Authority
AU
Australia
Prior art keywords
compositions
generating
methods
immune response
vector systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249380A
Inventor
Susan Barnett
David A Driver
Thomas W. Dubensky Jr.
Ilya Frolov
Jason P. Gardner
Gillis Otten
John M Polo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001249380A1 publication Critical patent/AU2001249380A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU2001249380A 2000-03-22 2001-03-22 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems Abandoned AU2001249380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19136300P 2000-03-22 2000-03-22
US60191363 2000-04-22
PCT/US2001/009326 WO2001081609A2 (en) 2000-03-22 2001-03-22 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Publications (1)

Publication Number Publication Date
AU2001249380A1 true AU2001249380A1 (en) 2001-11-07

Family

ID=22705178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249380A Abandoned AU2001249380A1 (en) 2000-03-22 2001-03-22 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Country Status (2)

Country Link
AU (1) AU2001249380A1 (en)
WO (1) WO2001081609A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (en) 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
CA2421683C (en) * 2000-09-28 2009-09-15 Chiron Corporation Microparticles for delivery of the heterologous nucleic acids
CA2420621C (en) 2000-09-28 2011-05-24 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
EP2305299B1 (en) 2001-05-31 2017-03-01 GlaxoSmithKline Biologicals SA Chimeric alphavirus replicon particles
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
US20100015211A1 (en) * 2004-11-01 2010-01-21 Barnett Susan W Combination Approaches For Generating Immune Responses
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
US20120040367A1 (en) 2007-10-15 2012-02-16 The University Of Queensland Construct system and uses therefor
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator

Also Published As

Publication number Publication date
WO2001081609A3 (en) 2002-02-28
WO2001081609A2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2001249380A1 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2000061772A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU2001268627A1 (en) Compositions and methods for generating expression vectors through site-specificrecombination
AU2008243079A1 (en) Compositions and methods for generating an immune response
AU2001255610A1 (en) System and method related to generating and tracking an email campaign
AU2001298063A1 (en) Methods and systems for generating business models
WO2002017157A8 (en) Marketing systems and methods
AU2001265154A1 (en) Method and composition for targeting an adenoviral vector
AU2001258701A1 (en) Systems and methods for presenting and/or converting messages
AU4806100A (en) P element derived vector and methods for its use
AU2001247496A1 (en) Methods and systems for providing an electronic account to customer
AU2001255205A1 (en) Systems and methods for generating computer-displayed presentations
AU2001231635A1 (en) Keep-fit device in the form of an item of clothing
MXPA03005579A (en) Branched primary alcohol compositions and derivatives thereof.
AU2003267279A1 (en) Systems and methods for transformable suits
AU2002248136A1 (en) Cloning vectors and vector components
AU3398701A (en) Set of equipment for the supplementation and forwarding of text messages
AU2002309486A1 (en) Methods and compositions for modulating the immune system of animals
AU1803401A (en) Methods and systems for generating tractograms
AU2001241996A1 (en) Rule based proximity and time based tracking system
AU2001275409A1 (en) Methods and compositions for controlled polypeptide synthesis
AU2001253481A1 (en) Methods and compositions for eleciting an immune response
WO2002102324A3 (en) Anti-arthropod vector vaccines methods of selecting and uses thereof
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU4866201A (en) Compositions and methods for use in modulating immune system function